Genome-wide binding of MBD2 reveals strong preference for highly methylated loci.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24927503.
- Also identified by DOI 10.1371/journal.pone.0099603 and PMC identifier 4057170.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MBD2 is a subunit of the NuRD complex that is postulated to mediate gene repression via recruitment of the complex to methylated DNA. In this study we adopted an MBD2 tagging-approach to study its genome wide binding characteristics. We show that in vivo MBD2 is mainly recruited to CpG island promoters that are highly methylated. Interestingly, MBD2 binds around 1 kb downstream of the transcription start site of a subset of ∼ 400 CpG island promoters that are characterized by the presence of active histone marks, RNA polymerase II (Pol2) and low to medium gene expression levels and H3K36me3 deposition. These tagged-MBD2 binding sites in MCF-7 show increased methylation in a cohort of primary breast cancers but not in normal breast samples, suggesting a putative role for MBD2 in breast cancer.
Medical subject headings
- Breast Neoplasms
- DNA Methylation
- DNA-Binding Proteins
- RNA Polymerase II